Repositioning HIV protease inhibitors as cancer therapeutics
WB Bernstein, PA Dennis - Current Opinion in HIV and AIDS, 2008 - journals.lww.com
Repositioning HIV protease inhibitors as cancer therapeutics : Current Opinion in HIV and AIDS
Repositioning HIV protease inhibitors as cancer therapeutics : Current Opinion in HIV and AIDS …
Repositioning HIV protease inhibitors as cancer therapeutics : Current Opinion in HIV and AIDS …
Stromal SPARC expression and patient survival after chemoradiation for non-resectable pancreatic adenocarcinoma
TS Mantoni, RRE Schendel, F Rödel… - Cancer biology & …, 2008 - Taylor & Francis
Purpose Pancreatic stellate cells (PSC) drive desmoplasia in pancreatic cancer. Our study
analyzed both tumor and PSC, since interaction of these cell types may promote tumor …
analyzed both tumor and PSC, since interaction of these cell types may promote tumor …
Nelfinavir induces TRAIL receptor upregulation in ovarian cancer cells
A Brüning, M Vogel, P Burger, M Rahmeh… - Biochemical and …, 2008 - Elsevier
HIV protease inhibitors are currently being discussed to be useful as new and alternative
anti-cancer agents, especially as second line treatments for chemo-resistant human cancer …
anti-cancer agents, especially as second line treatments for chemo-resistant human cancer …
A phase I radiation dose-escalation study to determine the maximal dose of radiotherapy in combination with weekly gemcitabine in patients with locally advanced …
T Budiharto, K Haustermans, E Van Cutsem… - Radiation …, 2008 - Springer
Background The primary objective of this study was to determine the maximum tolerated
dose (MTD) of escalating doses of radiotherapy (RT) concomitantly with a fixed dose of …
dose (MTD) of escalating doses of radiotherapy (RT) concomitantly with a fixed dose of …